173 related articles for article (PubMed ID: 38319329)
21. Response to Lenvatinib in Children with Papillary Thyroid Carcinoma.
Mahajan P; Dawrant J; Kheradpour A; Quintanilla NM; Lopez ME; Orth RC; Athanassaki I; Venkatramani R
Thyroid; 2018 Nov; 28(11):1450-1454. PubMed ID: 30226445
[TBL] [Abstract][Full Text] [Related]
22. Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma.
Iyer PC; Dadu R; Ferrarotto R; Busaidy NL; Habra MA; Zafereo M; Gross N; Hess KR; Gule-Monroe M; Williams MD; Cabanillas ME
Thyroid; 2018 Jan; 28(1):79-87. PubMed ID: 29161986
[TBL] [Abstract][Full Text] [Related]
23. Use of multikinase inhibitors/lenvatinib in singular thyroid cancer scenarios.
Zafón C; Castelo B
Cancer Med; 2022 Oct; 11 Suppl 1(Suppl 1):3-4. PubMed ID: 36202604
[TBL] [Abstract][Full Text] [Related]
24. Lenvatinib and Subsequent Therapy for Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Real-World Study of Clinical Effectiveness in the United States.
Kish JK; Chatterjee D; Wan Y; Yu HT; Liassou D; Feinberg BA
Adv Ther; 2020 Jun; 37(6):2841-2852. PubMed ID: 32382946
[TBL] [Abstract][Full Text] [Related]
25. Extended Real-World Observation of Patients Treated with Sorafenib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Impact of Lenvatinib Salvage Treatment: A Korean Multicenter Study.
Oh HS; Shin DY; Kim M; Park SY; Kim TH; Kim BH; Kim EY; Kim WB; Chung JH; Shong YK; Lim DJ; Kim WG
Thyroid; 2019 Dec; 29(12):1804-1810. PubMed ID: 31592739
[No Abstract] [Full Text] [Related]
26. Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer.
Herranz UA
Cancer Med; 2022 Oct; 11 Suppl 1(Suppl 1):47-53. PubMed ID: 36202606
[TBL] [Abstract][Full Text] [Related]
27. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
[TBL] [Abstract][Full Text] [Related]
28. Successful treatment switch from lenvatinib to sorafenib in a patient with radioactive iodine-refractory differentiated thyroid cancer intolerant to lenvatinib due to severe proteinuria.
Goto H; Kiyota N; Otsuki N; Imamura Y; Chayahara N; Suto H; Nagatani Y; Toyoda M; Mukohara T; Nibu KI; Kasahara T; Ito Y; Miya A; Hirokawa M; Miyauchi A; Minami H
Auris Nasus Larynx; 2018 Dec; 45(6):1249-1252. PubMed ID: 29779695
[TBL] [Abstract][Full Text] [Related]
29. Lenvatinib Compared with Sorafenib as a First-Line Treatment for Radioactive Iodine-Refractory, Progressive, Differentiated Thyroid Carcinoma: Real-World Outcomes in a Multicenter Retrospective Cohort Study.
Kim M; Jin M; Jeon MJ; Kim EY; Shin DY; Lim DJ; Kim BH; Kang HC; Kim WB; Shong YK; Kim HK; Kim WG
Thyroid; 2023 Jan; 33(1):91-99. PubMed ID: 35443825
[No Abstract] [Full Text] [Related]
30. Genetic mutations in thyroid carcinoma.
Taccaliti A; Boscaro M
Minerva Endocrinol; 2009 Mar; 34(1):11-28. PubMed ID: 19209125
[TBL] [Abstract][Full Text] [Related]
31. Novel Therapeutics for Advanced Differentiated Thyroid Cancer.
Lieberman L; Worden F
Endocrinol Metab Clin North Am; 2022 Jun; 51(2):367-378. PubMed ID: 35662446
[TBL] [Abstract][Full Text] [Related]
32. Redifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenib.
Rothenberg SM; McFadden DG; Palmer EL; Daniels GH; Wirth LJ
Clin Cancer Res; 2015 Mar; 21(5):1028-35. PubMed ID: 25549723
[TBL] [Abstract][Full Text] [Related]
33. A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine.
Fleeman N; Houten R; Chaplin M; Beale S; Boland A; Dundar Y; Greenhalgh J; Duarte R; Shenoy A
BMC Cancer; 2019 Dec; 19(1):1209. PubMed ID: 31830943
[TBL] [Abstract][Full Text] [Related]
34. Use of multikinase inhibitors/lenvatinib concomitant with locoregional therapies for the treatment of radioiodine-refractory differentiated thyroid cancer.
Berciano-Guerrero MÁ
Cancer Med; 2022 Oct; 11 Suppl 1(Suppl 1):40-46. PubMed ID: 36202609
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies.
Hong DS; Cabanillas ME; Wheler J; Naing A; Tsimberidou AM; Ye L; Busaidy NL; Waguespack SG; Hernandez M; El Naggar AK; Bidyasar S; Wright J; Sherman SI; Kurzrock R
J Clin Endocrinol Metab; 2011 Apr; 96(4):997-1005. PubMed ID: 21289252
[TBL] [Abstract][Full Text] [Related]
36. The Treatment of Well-Differentiated Thyroid Carcinoma.
Paschke R; Lincke T; Müller SP; Kreissl MC; Dralle H; Fassnacht M
Dtsch Arztebl Int; 2015 Jun; 112(26):452-8. PubMed ID: 26205749
[TBL] [Abstract][Full Text] [Related]
37. Clinical Outcomes of Radioactive Iodine Redifferentiation Therapy in Previously Iodine Refractory Differentiated Thyroid Cancers.
Toro-Tobon D; Morris JC; Hilger C; Peskey C; Durski JM; Ryder M
Thyroid; 2024 Jan; 34(1):70-81. PubMed ID: 37917101
[No Abstract] [Full Text] [Related]
38. An Era of Advances in Systemic Therapies for Advanced Thyroid Cancer.
Yun KM; Cohen EEW
JCO Oncol Pract; 2024 Mar; ():OP2300747. PubMed ID: 38452309
[TBL] [Abstract][Full Text] [Related]
39. Multikinase Inhibitors for the Treatment of Asymptomatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Global Noninterventional Study (RIFTOS MKI).
Brose MS; Smit JWA; Lin CC; Tori M; Bowles DW; Worden F; Shen DH; Huang SM; Tsai HJ; Alevizaki M; Peeters RP; Takahashi S; Rumyantsev P; Guan R; Babajanyan S; Ozgurdal K; Sugitani I; Pitoia F; Lamartina L
Thyroid; 2022 Sep; 32(9):1059-1068. PubMed ID: 35950621
[No Abstract] [Full Text] [Related]
40. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1.
Ricarte-Filho JC; Ryder M; Chitale DA; Rivera M; Heguy A; Ladanyi M; Janakiraman M; Solit D; Knauf JA; Tuttle RM; Ghossein RA; Fagin JA
Cancer Res; 2009 Jun; 69(11):4885-93. PubMed ID: 19487299
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]